Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?

Luca G. Guidotti; Carlo La Vecchia; Massimo Colombo

doi:10.1053/j.gastro.2020.09.007

Back

Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?

Article 2020 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2012

Chronotherapy With Low-Dose Aspirin for Prevention of Complications in Pregnancy

Diana E. Ayala, Rafael Ucieda, Ramon C Hermida

Article1993

Low‐dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy‐induced hypertension

Fabio Parazzini, Chiara Benedetto, T. Frusca, Gina Gregorini, Luca Bocciolone, Luca Marozio, María del Socorro Camarillo Romero, V Danesino, Giovanni de Gaetano, A Gastaldi, M Massobrio, Giuseppe Remuzzi, G Tognoni, Secondo Guaschino, Claire Bianchi, A. Valcamonico, M. Giambuzzi, D. Ammendola, Francesco Casucci

Letter2021

Low-dose rivaroxaban plus aspirin for elderly patients with symptomatic peripheral artery disease: is it worth the bleeding risk?

Juqian Zhang, S. Rao Vallabhaneni, Professor Gregory Lip

Chapter in a book2002

Interferon for the prevention of hepatocellular carcinoma

Jordi Bruix, María Sala, Josep M. Llovet

Letter2019

Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?

Aldo Maggioni, Felicita Andreotti